{
    "id": 13146,
    "fullName": "AIM2 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "AIM2 loss indicates loss of the AIM2 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 9447,
        "geneSymbol": "AIM2",
        "terms": [
            "AIM2",
            "PYHIN4"
        ]
    },
    "variant": "loss",
    "createDate": "10/21/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10389,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, rapamycin (sirolimus) prevented proliferation and colony formation of hepatocellular carcinoma cells with loss of Aim2 expression (PMID: 27167192).",
            "molecularProfile": {
                "id": 13317,
                "profileName": "AIM2 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8410,
                    "pubMedId": 27167192,
                    "title": "Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27167192"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7204,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colon cancer mouse model with loss of AIM2 demonstrated sensitivity to treatment with Triciribine (API-2), resulting in a decreased number of colon polyps and a reduced tumor load (PMID: 26107252).",
            "molecularProfile": {
                "id": 13317,
                "profileName": "AIM2 loss"
            },
            "therapy": {
                "id": 948,
                "therapyName": "Triciribine",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3781,
                    "pubMedId": 26107252,
                    "title": "Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26107252"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13317,
            "profileName": "AIM2 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 10964,
                    "name": "Triciribine",
                    "profileName": "AIM2 loss"
                },
                {
                    "id": 10963,
                    "name": "Sirolimus",
                    "profileName": "AIM2 loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}